The association between hormonal therapy resistance and CAFs in NSCLC should be considered because CAFs are known to affect the efficacy of hormone therapy in breast and prostate cancers by modulating estrogen and androgen sensitivity of cancer cells, maintaining a hormone-dependent microenvironment, or affecting the expression and activation of hormone receptors [97,98,99,100,101]. Here, NR4A1 is linked to cancer.